OQROGet OQRO Pro
Insider trade

Stoke Therapeutics (STOK)CHIEF MEDICAL OFFICER sold ~$52K

Barry Ticho, CHIEF MEDICAL OFFICER at Stoke Therapeutics, sold ~$52K of Stoke Therapeutics shares.

~$52K
Approx. value · 4,503 sh @ $11.63
21K
Holds after · shares reported
Traded
Jul 1, 2025
Filed
Jul 2, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 1, 2025InsiderOfficer sold ~$38K of STOK shares in the open market
  2. May 2, 2025InsiderOfficer sold ~$229K of STOK shares in the open market
  3. Jun 2, 2025InsiderOfficer sold ~$17K of STOK shares in the open market
  4. Jun 3, 2025InsiderOfficer sold ~$65K of STOK shares in the open market
  5. Jun 4, 2025Insider10% owner sold ~$30.6M of STOK shares in the open market
  6. Jul 1, 2025 · this disclosureInsiderOfficer sold ~$52K of STOK shares in the open market

What came next

  1. Aug 1, 2025InsiderOfficer sold ~$58K of STOK shares in the open market
  2. Aug 13, 2025InsiderOfficer sold ~$206K of STOK shares in the open market
  3. Aug 18, 2025Insider · 3 peopleInsiders: 3 sales (~$303K)
  4. Aug 29, 2025Insider · 2 peopleInsiders: 2 sales (~$38K)
  5. Sep 2, 2025Insider · 3 peopleInsiders: 3 sales (~$709K)
  6. Sep 3, 2025Insider · 2 peopleInsiders: 2 sales (~$1.1M)
  7. Oct 5, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 5, 2025, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) appointed Ian F. Smith, who has been serving as the Company’s Interim Chief Executive Officer since March 19, 2025, as the Company’s permanent Chief Executive Officer and principal executive officer (the “Smith Appointment”), effective as of October 6, 2025 (the “Effective Date”).”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Stoke Therapeutics

For Stoke Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its STOK page.

Other recent filings by Barry Ticho, CHIEF MEDICAL OFFICER

The full history of Barry Ticho, CHIEF MEDICAL OFFICER is on the profile page.

How this filing works

Other disclosures at Stoke Therapeutics

Everything OQRO holds on this company is on its STOK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data